Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of High-dose CKD-385 in Healthy Volunteers
NCT04083872Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-385 in hypertension (HTN) and cardiovascular diseases (CVD) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last and Maximum Plasma Concentration. Started Sep 2019; status: completed.
02
Drugs
CKD-385
03
Conditions
hypertension (HTN)cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04083872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083872.